Please login to the form below

Not currently logged in
Email:
Password:

Brintellix

This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.

Lundbeck launches Brintellix in first EU market

Lundbeck launches <b>Brintellix</b> in first EU market

Lundbeck launches Brintellix in first EU market. The antidepressant set to sell worldwide. ... Danish pharma company Lundbeck is selling its new antidepressant Brintellix in its home market, the first European launch for the product.

Latest news

  • EMA backs Lundbeck's <b>Brintellix</b> in depression EMA backs Lundbeck's Brintellix in depression

    EMA backs Lundbeck's Brintellix in depression. Drug recommended for approval to treat major depressive episodes in adults. ... In the latest round of EU drug recommendations, Lundbeck won backing for the use of Brintellix in the treatment of adult

  • Lundbeck buoyed by <b>Brintellix</b> approval in US Lundbeck buoyed by Brintellix approval in US

    Lundbeck buoyed by Brintellix approval in US. FDA gives green light for to Cipralex/Lexapro successor in depression. ... Lundbeck was celebrating yesterday after the FDA approved its new antidepressant Brintellix, a successor to the big-selling

  • Lundbeck and Takeda submit depression drug for US approval Lundbeck and Takeda submit depression drug for US approval

    Lundbeck and Takeda submit depression drug for US approval. Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex. ... Lundbeck's plans to find a replacement for its big-selling antidepressant Lexapro/Cipralex continue

  • Pharma spent $342m on journal advertising in first half of 2014 Pharma spent $342m on journal advertising in first half of 2014

    J&J spent $12m to advertise the drug, which was approved in the US in April 2013, was up 84 on the same period in 2013, while Lundbeck's antidepressant Brintellix was

  • Otsuka and Lundbeck file Abilify follow-up in the US Otsuka and Lundbeck file Abilify follow-up in the US

    Brexipiprazole is one of a trio of new drugs Lundbeck and alliance partner Otsuka are relying on to drive growth in the coming years, alongside recently launched antidepressant Brintellix ( vortioxetine) and

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Bayer’s Barbara Jaszewski joins Lundbeck Bayer’s Barbara Jaszewski joins Lundbeck

    In addition, Lundbeck also has Brintellix ( vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify ( aripiprazole) is also due to launch during 2013.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Uptake Strategies

We are a specialist healthcare marketing consultancy generating competitive strategies underpinned with excellent customer insight, clear objectives and measures of...

Latest intelligence

Online Physician Communities
M3 and partners win Digital Sales Aid Award
Wins for campaign to overcome limited doctor engagement with pharma-owned websites...
UK Customer Experience Awards 2014 Highlights
Stephanie Hall, Managing Director at Uptake Strategies, attended this year’s cross-industry UK Customer Experience Awards as a member of the judging panel for Business Transformation....
McCann3-thumb.jpg
The heart of the matter - Part Three
Is pharma doing enough to maximise real world evidence?...